Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy

Abstract Background Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited....

Yi-Shao Liu, P. Desai, H. Khurshid et al. · 0 citations
Open access Oct 2026

Real-world treatment patterns, outcomes, and burden of early progression in small cell lung cancer (SCLC) in the US.

704 Background: Treatment options for patients with SCLC are limited, and prognosis remains poor. Most patients develop resistance to or relapse after first-line (1L) therapies within the first year in both limited-stage (LS) and extensive-stage (ES). The economic burden of SCLC is not well characterized. This...

Su Zhang, Franziska Dirnberger, Sunny Ubi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.